Embryotoxic effects of SKI 2053R, a new potential anticancer agent, in rats

Reproductive Toxicology

Volumn 12, Issue 3, 1998, Pages 375-381

  Chung, Moon Koo ^a   Kim, Jong Choon ^a   Roh, Jung Koo ^a  

^a Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

Anticancer agent; Embryotoxicity study; Rats; SKI 2053R

Indexed keywords

ANTINEOPLASTIC AGENT; MALONIC ACID DERIVATIVE; PLATINUM 4,5 BIS(AMINOMETHYL) 2 ISOPROPYL 1,3 DIOXOLANE MALONATE; PLATINUM COMPLEX;

ANIMAL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CESAREAN SECTION; CHEMICAL STRUCTURE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EMBRYO; EMBRYO DEVELOPMENT; EMBRYOTOXICITY; FEMALE; FETUS DEVELOPMENT; GESTATIONAL AGE; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MALFORMATION SYNDROME; NONHUMAN; ORGAN WEIGHT; PREGNANCY; RAT; RAT STRAIN; TOXICITY TESTING;

EID: 0032081176     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(98)00016-1     Document Type: Article

References (27)

1. Tanaka H, Ishikawa E, Teshima S, Shimizu E. Histopathological study of human cisplatin nephrotoxicity. Toxicol Pathol. 14:1986;247-257.
2. Fillastre JP, Raguenz-Viotte G. Cisplatin nephrotoxicity. Toxicol Lett. 46:1989;163-175.
3. Harrap KR. Preclinical studies identifying carboplatin as a visible cisplatin alternative. Cancer Treat Rev. 12:(Suppl A):1985;21-33.
4. Rose WC, Schurig JE. Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat Rev. 12:(Suppl. A):1985;1-19.
5. Platinum. Environ Health Criteria. 125:1991;167.
6. Kim DK, Kim G, Gam J, Cho YB, Kim HT, Tai JH, Kim KH, Hong WS, Park JG. Synthesis and antitumor activity of a series of [2-substituted-4,5-bis(aminomethyl)-1,3-dioxolane]platinum(II) complexes. J Med Chem. 37:1994;1471-1485.
7. Kim DK, Kim HT, Cho YB, Tai JH, Ahn JS, Kim TS, Kim KH, Hong WS. Antitumor activity of cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) , a new platinum analogue, as an anticancer agent. Cancer Chemother Pharmacol. 35:1995;441-445.
8. Hong WS, Kim HT, Kim KH, Kim DK. In vitro antitumor activity of a new platinum complex, cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) (SKI 2053R), against human lung and stomach cancer cell lines. Anticancer Res. 15:1995;51-54.
9. Kim DK, Kim HT, Tai JH, Cho YB, Kim TS, Kim KH, Park JG, Hong WS. Pharmacokinetics and antitumor activity of a new platinum compound, cis-Malonato [(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane] platinum(II), as determined by ex vivo pharmacodynamics. Cancer Chemother Pharmacol. 37:1995;1-6.
10. Kim DK, Ahn JS, Ryu KH, Kim CW, Park MS, Kim MH, Chung MH, Shin SG, Suh YH, Kim YS. General pharmacology of cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) . Drug Res. 44:1994;1080-1088.
11. Kang KS, Shin DJ, Cho JJ, Kim HO, Kim BH, Lee YS. Acute toxicity of cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) (SKI 2053R) in rats and mice. Korean J Toxicol. 8:1992;205-216.
12. Kim HO, Kang KS, Shin DJ, Cho JJ, Kim BH, Seo KW, Nam KH, Lee YS. Subacute toxicity of cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) (SKI 2053R) in rats. Korean J Toxicol. 8:1992;217-233.
13. Lee YS, Kang KS, Shin DJ, Cho JJ, Kim HO, Kim BW, Lim YK. Subacute toxicity of cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-isopropyl-1,3-dioxolane]platinum(II) (SKI 2053R) in beagle dogs. Korean J Toxicol. 8:1992;235-253.
14. Kopf-Maier P. Stage of pregnancy-dependent transplacental passage of 195mPt after cis-platinum treatment. Eur J Cancer Clin Oncol. 19:1983;533-536.
15. Cho YB, Kim KH, Kim DK, Miyamoto G. Mammary excretion and placental transfer of cis-Malonato[(4R,5R)-4,5-bis(aminomethyl)-2-Isopropyl-1,3-Dioxolane]Platinum(II) in rats. Drug Res. 46:1996;926-930.
16. Muranaka R, Fukiishi Y, Tsuiki Y, Hasegawa Y. Teratogenic characteristics by single dosing of antineoplastic platinum complexes in rats. Teratology. 44:1991;7B-8B.
17. Keller KA, Aggarwal SK. Embryotoxicity of cisplatin in rats and mice. Toxicol Appl Pharmacol. 69:1983;245-256.
18. Anabuki K, Kitazima S, Koda S, Takahashi N. Reproductive studies on cisplatin. Yakuri to Chiryo. 10:1982;659-701.
19. Dawson AB. A note on the staining of the skeleton of cleared specimens with alizarin red S. Stain Technol. 1:1926;123-124.
20. Wilson JG. Methods for administering agents and detecting malformations in experimental animals in teratology. Wilson JG. Principles and techniques. 1965;262-277 University of Chicago Press, Chicago.
21. Nishimura K. A microdissection method for detecting thoracic visceral malformations in mouse and rat fetuses. Cong Anom. 14:1974;23-40.
22. Scheff H. A method of judging all contrasts in the analysis of variance. Biometika. 40:1953;87-104.
23. Manson JM, Kang YJ. Test methods for assessing female reproductive and developmental toxicology. Hayes W, et al. Principles and methods of toxicology. 1989;311-359 Raven Press, New York.
24. Morita H, Ariyuki F, Inomata N, Nishimura K, Kasegawa Y, Miyamto M, Watanabe T. Spontaneous malformations in laboratory animals frequency of external, internal and skeletal malformations in rats, rabbits and mice . Cong Anom. 27:1987;147-206.
25. Bajt ML, Aggarwal SK. An analysis of factors responsible for resorption of embryos in cisplatin-treated rats. Toxicol Appl Pharmacol. 80:1985;97-107.
26. Muranaka R, Fukiishi Y, Tsuiki Y, Hirashiba M, Ueyama T, Kitagawa T, Hasegawa Y, Kishi K. Factors responsible for embryolethality in antineoplastic platinum complex-treated rats. Teratology. 48:1993;511.
27. Kopf-Maier P, Erkenswick P, Merker HJ. Lack of severe malformations versus occurrence of marked embryotoxic effects after treatment of pregnant mice with cis-platinum. Toxicology. 34:1985;321-331.